STiPS-M001
SCTi002-A
General
Cell Line |
|
| hPSCreg name | SCTi002-A |
| Cite as: | SCTi002-A (RRID:CVCL_9S50) |
| Alternative name(s) |
STiPS-M001
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines | No similar lines found. |
| Last update | 9th December 2024 |
| User feedback | |
Provider |
|
| Generator | STEMCELL Technologies Inc. (SCT) |
| Derivation country | Canada |
External Databases |
|
| Cellosaurus | CVCL_9S50 |
| Wikidata | Q54952676 |
General Information |
|
| Publications | |
| Projects | |
| * Is the cell line readily obtainable for third parties? |
No |
Donor Information
General Donor Information |
|
| Sex | male |
Phenotype and Disease related information (Donor) |
|
| Diseases | No disease was diagnosed.
|
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
No
|
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | No |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | No |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | No |
| If you do not hold the Donor Consent Form, do you know who does? | Yes |
| Alternatives to consent | |
| Alternative consent approval number | |
| Has the donor agreed to be re-contacted? | No |
| Has the donor been informed about how her/his data will be protected? | No |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | No |
| * Does consent expressly prevent the derivation of pluripotent stem cells? | Yes |
| * Does consent pertain to a specific research project? | No |
| Details on restriction to research project | |
| Does consent permit unforeseen future research, without further consent? | No |
| Does the consent permit uses of donated embryo/tissue or derived cell line intended for clinical treatment or human applications? | No |
| Does consent expressly permit storage of donated embryo/tissue for an unlimited time? | Yes |
| Does consent prevent the DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | Yes |
Does consent permit research by | |
| an academic institution? | Yes |
| a public organisation? | Yes |
| a non-profit company? | Yes |
| a for-profit corporation? | Yes |
| Does consent expressly permit collection of genetic information? | Yes |
| Has the donor been informed that their donated biosample or derived cells may be tested for the presence of microbiological agents / pathogens? | Yes |
| How may genetic information associated with the cell line be accessed? | |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Does consent permit access to medical records of the donor? | No |
| Please describe how access is provided: | |
| Does consent permit access to any other source of information about the clinical treatment or health of the donor? | No |
| Contact data, institution, or website: | |
| Name of accrediting authority involved? | Internal Review - for-profit company |
| Approval number | |
| Name of accrediting authority involved? | Internal Review - for-profit company |
| Approval number | |
| Do you have obligations to third parties in regard to the use of the cell line? | No |
| Please describe: | |
| Are you aware of any further constraints on the use of the donated embryo/tissue or derived cells? | No |
| Further constraints on use | |
| Is there an MTA available for the cell line? | No |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | Dr Shinya Yamanaka |
| Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? | Yes |
| Constraints for use or distribution | Not for commercial use, sale or distribution |
hIPSC Derivation
General |
|
| Source cell type |
A stromal cell that is part_of a bone marrow.
Synonyms
|
| Source cell origin |
The soft tissue that fills the cavities of bones.
Synonyms
|
| Source cell type (free text) | Bone Marrow Derived Mesenchymal Stromal Cell |
| Source cell line vendor | LONZA |
| Passage number reprogrammed | 14 |
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Episomal |
| Genes | |
Vector free reprogramming |
|
Other |
|
| Selection criteria for clones | Clones were picked based on morphology |
| Derived under xeno-free conditions |
No |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
Culture Conditions
| Surface coating | Matrigel/Geltrex |
| Feeder cells |
No |
| Passage method | Enzyme-free cell dissociation |
| O2 Concentration | 20 % |
| CO2 Concentration | 10 % |
| Medium |
mTeSR™ 1
|
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| POU5F1 (OCT-4) |
Yes |
|
|
|||
| SSEA-3 |
Yes |
|
|
|||
| TRA 1-81 |
Yes |
|
|
Differentiation Potency
Microbiology / Virus Screening |
|
| HIV 1 | Negative |
| HIV 2 | Negative |
| Hepatitis B | Negative |
| Hepatitis C | Negative |
| Mycoplasma | Negative |
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
Normal
Passage number: 12
Karyotyping method:
G-Banding
|
Other Genotyping (Cell Line) |
|
Login to share your feedback, experiences or results with the research community.